Isothermal Nucleic Acid Amplification Technologies (INAAT) Market (2012 – 2017) - (Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing)
Publishing Date: October 2012
Report Code: PH 1302
The research analysis titled “Isothermal Nucleic Acid (Gene) Amplification Technologies (INAAT)” discloses the promising trends in Nucleic acid testing and their applications in molecular diagnostics and laboratory research on a global scale. The World Health Organization (WHO) proposes that, an ideal diagnostic test (DNA test kits, RNA test kit etc) that is suitable for developing countries, should be Affordable, Sensitive, Specific and User-friendly (simple to perform in a few steps with minimal training), Robust and rapid (results available in minutes), Equipment free and Deliverable to the end-user (ASSURED). Nucleic acid diagnostics targeting pathogen markers have high sensitivity and specificity, but generally fail to meet the ASSURED guidelines in terms of affordability, rapidity, and being equipment free. However, non-PCR based technologies like Isothermal amplification of nucleic acids has recently attracted the scientific community due to their operation in single temperature and distinct features by meeting the ASSURED guidelines. With fine-tunings in the amplification methodology, a variety of INAAT types are discovered each being independent, driving the diagnostic platform towards Point-of-Care Testing (POCT) at low resource settings.
This research report provides in-depth details about technology evolution, and innovation trends across the industry, technology investment potential and competitive market landscape. The analyses ensuing out of this research service may provide, useful insights for end users, while prioritizing the appropriate choice of modality for detection of nucleic acids in research and diagnostics.
In brief, this research report provides:
- A detailed description of the global technology developments and evolving trends, in the INAAT field with key prominence on product innovations by industries, and collaborative efforts by the academic research institutions.
- A comprehensive picture of the different types of INAAT platforms (LAMP (loop-mediated isothermal amplification), NASBA (nucleic acid sequence based amplification), SDA (strand displacement amplification), TMA (transcription mediated amplification), SPIA (single primer isothermal amplification), HDA (helicase dependent amplification) available with an exhaustive overview of their application prospective. Alternative terminologies currently in use for the above mentioned technologies include: isothermal dna amplification, loop-mediated isothermal amplification of dna, tma amplification, strand displacement assay, nasba assay.
- An impact analysis of major drivers, restraints and challenges influencing the adoption and growth of INAAT during the period from 2012 to 2017.
- Market size - Global market forecast for the next 5 years, including demand side analysis and strategic recommendations for technology/product developers.
- Prioritized INNAT types through the Analytical Hierarchy Process (AHP) based on competitive benchmarking, technology management strategies and technology roadmap.
- Competitive landscape based on the analysis of key patents and research publications that gives an insight into prominent activities and global participants.
TABLE OF CONTENTS
1.1 KEY TAKE-AWAYS
1.2 REPORT SCOPE
1.3 RESEARCH METHODOLOGY
1.4 KEY DATA SOURCES
2 EXECUTIVE SUMMARY
3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (INAAT) – TECHNOLOGY LANDSCAPE ANALYSIS
3.1 TECHNOLOGY OVERVIEW (LAMP, NASBA, SDA, TMA, SPIA, HDA)
3.2 INAAT VS PCR – COMPETITIVE ADVANTAGES
3.3 TECHNOLOGY VALUE CHAIN ANALYSIS
3.4 COMPARATIVE ANALYSIS OF INAAT TYPES
3.5.1 INAAT - MOLECULAR DIAGNOSTICS
184.108.40.206. Infectious Disease Diagnostics
220.127.116.11. Blood Screening
3.5.2 INAAT - RESEARCH APPLICATIONS
18.104.22.168 Laboratory Research
22.214.171.124 Cancer Research
3.6 PRODUCT/TECHNOLOGY INNOVATIONS - APPLICATIONS
4 TECHNOLOGY INVESTMENT POTENTIAL
4.1 INVESTMENT CLIMATE ASSESSMENT
4.1.1 INVESTOR NETWORK
126.96.36.199 Public Funding Bodies
188.8.131.52 Philanthropic Bodies
184.108.40.206 Private Investors & Venture Capital Firms
220.127.116.11 Insights on Current & Future Tech-Investment Trends
18.104.22.168 Some of The Funds & Investments on INAAT
4.2.1 INVESTMENT OPPORTUNITIES
22.214.171.124 Evaluation of Technologies Available For Licensing & Acquisition For Stakeholders
126.96.36.199 Analysis of Potential Application Areas For Technology Investment Using OSE Grid
5 INAAT - MARKET LANDSCAPE ANALYSIS
5.1 MARKET SEGMENTATION
5.2 INAAT MARKET SHARE IN MOLECULAR DIAGNOSTICS MARKET
5.3 GLOBAL MARKET FORECAST
5.3.1 BY GEOGRAPHY
5.3.2 BY APPLICATIONS
5.4 MARKET DYNAMICS
5.4.4 CURRENT & EMERGING OPPORTUNITIES
5.5 DEMAND SIDE ANALYSIS
6 INAAT – TECHNOLOGY ADOPTION POTENTIAL & DEVELOPMENT BY GEOGRAPHY
6.1 TECHNOLOGY ADOPTION & DEVELOPMENT – KEY FINDINGS
6.2 NORTH AMERICA
6.5 REST OF THE WORLD
6.6 REGIONS WITH HIGH TECHNOLOGY ADOPTION
7 COMPETITIVE LANDSCAPE
7.1 MERGERS & ACQUISITIONS (2007-2012)
7.2 PARTNERSHIPS & COLLABORATIONS (2007-2012)
7.3 NEW PRODUCT DEVELOPMENT INITIATIVES – 2012
7.3.1 LIST OF NEW APPROVED INAAT PRODUCTS – 2012
7.3.2 INAAT PRODUCTS – IN-PIPELINE
7.3.3 RESEARCH INNOVATIONS
8 PATENT ANALYSIS AND RESEARCH TREND (PUBLICATIONS) 2007-2012
8.1 PATENT LANDSCAPE ANALYSIS (2007-2012)
8.2 RESEARCH LANDSCAPE (2007-2012)
9 TECHNOLOGY ANALYSIS (USING AHP) & ROAD MAPPING
10 ANALYST INSIGHTS & RECOMMENDATIONS
10.1 STRATEGIC RECOMMENDATIONS FOR TECHNOLOGY & BUSINESS MANAGEMENT
10.2 KEY INVITATIONS & OPPORTUNITIES
11 COMPANY PROFILES
11.1 BECTON, DICKINSON AND COMPANY (BD)
11.4 EIKEN CHEMICAL CO., LTD.
11.5 HOLOGIC GEN-PROBE
11.7 MERIDIAN BIOSCIENCE INC
11.8 NEW ENGLAND BIOLABS
11.9 NOVARTIS DIAGNOSTICS
11.13 USTAR BIOTECHNOLOGIES (HANGZHOU) LTD.
LIST OF TABLES
TABLE 1 NIH FUNDING DETAILS AND ESTIMATION IN INFECTIOUS DISEASES DURING THE FISCAL YEAR (FY) 2010 –2013
TABLE 2 NIH AND CDC TOTAL FUNDS TOWARDS INFECTIOUS DISEASES
TABLE 3 GATES FOUNDATION GRANTS (1994 TO 2009)
TABLE 4 FUNDS AND INVESTMENTS ON INAAT
TABLE 5 MERGERS AND ACQUISITIONS (2007-2012)
TABLE 6 PARTNERSHIPS AND COLLABORATIONS (2007-2012)
TABLE 7 LIST OF NEW APPROVED INAAT PRODUCTS
TABLE 8 INAAT PRODUCTS – IN PIPELINE
TABLE 9 KEY PATENTS
TABLE 10 CURRENT RESEARCH IN INAAT
LIST OF FIGURES
FIGURE 1 MARKET REVENUE FORECAST OF INAAT IN LINE WITH MOLECULAR DIAGNOSTICS
FIGURE 2 INAAT CAPABILITY TOWARDS POCT
FIGURE 3 INAAT PRODUCTS CURRENTLY AVAILABLE FOR INFECTIOUS DISEASES
FIGURE 4 NIH AND CDC TOTAL FUNDS TOWARDS INFECTIOUS DISEASES
FIGURE 5 INAAT MARKET SHARE IN MOLECULAR DIAGNOSTICS (MDX)
FIGURE 6 MARKET SHARE (%) AND REVENUES ($ MILLION) BY REGION (2012)
FIGURE 7 MARKET SHARE (%) AND REVENUES ($ MILLION) BY REGION (2017)
FIGURE 8 MARKET SHARE (%) AND REVENUES ($ MILLION) BY APPLICATIONS (2012)
FIGURE 9 MARKET SHARE (%) AND REVENUES ($ MILLION) BY APPLICATIONS (2017)
FIGURE 10 NO. OF PATENTS PUBLISHED BETWEEN THE YEARS 2007-2012
FIGURE 11 COMPARATIVE ANALYSIS OF PAPERS PUBLISHED FOR INDIVIDUAL TECHNOLOGY BETWEEN 2007-2012
FIGURE 12 RESEARCH PAPERS PUBLISHED BETWEEN THE YEARS (2007-2012)
FIGURE 13 PRIORITY VALUES FOR LEVEL 0
FIGURE 14 COMPARISON OF TECHNOLOGY BASED ON LEVEL 0 CRITERIA
FIGURE 15 RANKING VALUES RECEIVED BY THE TECHNOLOGIES
Molecular diagnostic segment is one of the fastest growing segments in Diagnostics market with a potential market value of over US$8.1billion by 2017. One of the premier growing segments in molecular diagnostics is the nucleic acid testing. Over two decades PCR has been dominated as the standard tool for detection in blood transfusion, genetic testing and other disorders. Yet, with changes in the industry outlook towards a cost effective, rapid and reliable means of detection has posed a limitation to the use of PCR. Isothermal Nucleic Acid Technology (INAAT) addresses this growing demand with new developments towards point of care use.
It is worthy to mention that INAAT existed in parallel with PCR and yet its market potential was never exploited to the extent of PCR. With growing demand and technological advances INAAT is poised to grow on par with PCR in next five years timeline. Favorable regulatory landscape, untapped markets, end user acceptance are largely in favor of INAAT. However apprehensions about the market performance and perception of competing with PCR have limited the investments potential to government agencies, NGO’s, etc.
With new products in development and others awaiting their launch in market, the time period from 2012 to 2015 will determine the outcome of its true potential.The estimated global value of INAAT is around US$1.6 billion in 2017 at a growing CAGR of 17%. INAAT has a strong market presence in U.S., Canada and Europe. This trend is expected to peak over the next ten years.
New markets for INAAT that are expected to grow at a rapid pace are China, India, South Africa and other regions of Asia pacific, Africa and untapped markets of Europe. The Key Players in this market are Hologic-Gen-Probe, bioMerieux, BD Diagnostics, Qiagen, Alere, Eiken Chemical, Meridian Bioscience, BioHelix and Quidel.
INAAT Market Share, By Geography, 2012 and 2017
Source: MarketsandMarkets Analysis
The analysis indicated that companies who make strategic decisions through licensing agreements, tie ups with research institutes towards developments in new technological platforms, acquisition and developing strategic alliances with key stakeholders are poised to capture the market.